Opinion Paper/CommentaryRe: Aducanumab-Related ARIA: Paean or Lament?Wassef, Heidi R. MD; Colletti, Patrick M. MD Author Information From the Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Keck School of Medicine of USC, Los Angeles, CA. Received for publication October 5, 2022; revision accepted October 8, 2022. Conflicts of interest and sources of funding: none declared. Correspondence to: Heidi R. Wassef, MD, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Keck School of Medicine of USC, 1510 San Pablo St, Los Angeles, CA 90089. E-mail: [email protected]. Clinical Nuclear Medicine 48(2):p 168-169, February 2023. | DOI: 10.1097/RLU.0000000000004490 Buy Metrics Abstract Høilund-Carlsen and colleagues raise concern regarding the reliability of amyloid PET to exclude Alzheimer disease. We present additional studies of amyloid PET and discuss the diagnostic challenges in Alzheimer disease. We discuss the limitations of amyloid in diagnosis and evaluation of therapy response in AD. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.